荷兰血友病患者中B19型细小病毒IgG抗体的高流行率。

High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.

作者信息

Mauser-Bunschoten E P, Zaaijer H L, van Drimmelen A A, de Vries S, Roosendaal G, van den Berg H M, Lelie P N

机构信息

Van Creveld Clinic, University Hospital Utrecht, The Netherlands.

出版信息

Vox Sang. 1998;74(4):225-7.

PMID:9691402

Abstract

BACKGROUND AND OBJECTIVES

Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products.

MATERIALS AND METHODS

To determine the prevalence of the corresponding antibody in patients with hemophilia A or B von Willebrand's disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children).

RESULTS

The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was significantly lower incidence in patients who were rarely treated.

CONCLUSION

Parvovirus B19 if frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission.

摘要

背景与目的

人细小病毒B19对接受血液制品的血友病患者存在潜在风险。

材料与方法

为确定甲型血友病或B型血管性血友病患者中相应抗体的流行情况，我们对326例血友病患者进行了抗B19 IgG检测。将结果与203例年龄匹配的对照者（男性献血者和儿童）的结果进行比较。

结果

血友病患者中B19 IgG的总体流行率为302/326，对照者中为123/203。10岁以下的血友病患者中B19 IgG的流行率（76%，42/55）高于对照者（23%，11/48；p<0.00001）。在5岁以下仅接受单克隆纯化浓缩物治疗的患者中，产品是经过巴氏消毒还是溶剂去污剂处理并无差异。很少接受治疗的患者发病率显著较低。